Relevance. The problem of treatment and prevention of microvascular complications against the background of hyperglycemia is much broader than adherence to an appropriate diet. It is necessary to take into account both the behavioral characteristics of a person and the genetically determined mechanisms of metabolic regulation.
Objective to study the behavioral and genetically determined differences in patients with type 2 diabetes mellitus complicated by retinopathy with different PPARG-dependent phenotype.
Materials and methods. The study included 101 patients with type 2 diabetes mellitus (T2DM), who, according to the results of an ophthalmological examination, revealed various stages of diabetic retinopathy (DR) according to the ETDRS scale. The control group (CG) included 40 people without diabetes, comparable to patients by gender, age, and body mass index. Gene polymorphism was determined using real-time PCR on an automatic amplifier Gene Amp® PCR System 7500, the fatty acid spectrum (FA) was determined using gas-liquid chromatography, and behavioral and nutritional habits were analyze according to the results of a questionnaire.
Results. In patients with type 2 diabetes, the most effective way to correct hyperglycemia at all stages of development of complications was the use of insulin in tablet forms. Carriers of the PPARG gene polymorphism had greater stability in achieving the target blood glucose level. The carriers of the wild genotype Pro12Pro did not differ from the CG in the rationality of nutrition and lifestyle. Carriers of the 12Ala allele were characterized by a neglect of food recommendations at the beginning of the disease, but with the progression of the degree of microvascular complications, the awareness of the need for proper nutrition doubled (P <0.05). Their lifestyle was initially less rational than that of carriers of the wild genotype Pro12Pro, but the course of T2DM and the development of complications in the form of DR by 2–3 times (P <0.05) reduced the desire for a healthy lifestyle.
2. Boden G, Laakso M. Lipids and Glucose in Type 2 Diabetes. What is the cause and effect? // Diabetes Care 2004; 27 (9): 2253-9. https://doi.org/10.2337 / diacare.27.9.2253
3. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres // Nature. 2002; 418 (6899): 797-801. https://doi.org/10.1038/nature00904
4. Fu S, Meng Y, Zhang W, et al. Transcriptomic Responses of Skeletal Muscle to Acute Exercise in Diabetic Goto-Kakizaki Rats // Front Physiol. 2019; 10: 872. https://doi.org/10.3389/fphys.2019.00872
5. Grimaldi PA. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives // Cell Mol Life Sci. 2007; 64 (19-20): 2459-64. https://doi.org/10.1007 / s00018-007-7278-5
6. Zierath JR, Ryder JW, Doebber T, et al. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action // Endocrinology. 1998; 139: 5034-41. https://doi.org/10.1210/endo.139.12.6364
7. Deeb SS, Fajas L, Nemoto M, et al., A Pro12Ala substitution in the human PPARγ2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index // Nat Genet. 1998. 20: 284-7 https://doi.org/10.1038 / 3099
8. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP-kinase mediated phosphorylation of PPARγ // Science. 1996; 274: 2100-3. https://doi.org/10.1126 /science.274.5295.2100
9. Tuomilehto J, Lindstrom J, Eriksson JG, et al., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344: 1343-50. https://doi.org/10.1056/NEJM200105033441801
10. Blaschke F, Takata Y, Caglayan E, et al. Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes // Arteriosclerosis, Thrombosis and Vascular Biology. 2006; 26: 28-40. https://doi.org/10.1161 / 01.ATV.0000191663.12164.77
11. Mann J.I. Nutrition recommendations for the treatment and prevention of type 2 diabetes and the metabolic syndrome: an evidenced-based review // Nutr. Rev. 2006; 64 (9): 422-7. https://doi.org/10.1111 / j.1753-4887.2006.tb00227.x
12. Risérus U, Willett WC, Hu FB. Dietary fats and prevention of type 2 diabetes // Prog Lipid Res. 2009; 48 (1): 44-51. https://doi.org/10.1016 / j.plipres.2008.10.002
13. Kaydashev IP, Rasin AM, Shlykova OA, et al. Frequency Pro12Ala PPARγ2 gene polymorphism in Ukrainian population and its possible link to development metabolic syndrome // Tsitologiya i genetika. 2007; 5: 43-7. [in Russia] http://cytgen.com/articles/4150043a.pdf
14. Ziablytsev SV, Mokrii VY. Association between allele 12Pro of rs1801282 polymorphism gene PPAR and diabetes mellitus type 2 // Clinical Endocrinology and Endocrine Surgery. 2016; 3 (55): 34-8. [in Ukrainian]. https://doi.org/10.24026/1818-1384.3(55).2016.77483
15. Weijers Rob N.M. Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus // Curr Diabetes Rev. 2012; 8 (5): 390-400. https://doi.org/10.2174 / 157339912802083531
16. Hussein JS. Cell membrane fatty acids and health // Int. J. Pharm. Sci. 2013; 5 (Suppl. 3): 38-46. https://innovareacademics.in/journal/ijpps/Vol5Suppl3/7389.pdf
17. Rykov SO, Bykhovets MY, Natrus LV. Features of the lifestyle as a factor of the risk of development and progression of diabetic retinopathy in patients with diabetes mellitus of 2 types // Archive of Ophthalmology of Ukraine. 2019; 7 (1): 54-61. https://doi.org/10.22141/2309-8188.8.131.529.163000
18. Salas-Salvadó J, Martinez-González MÁ, Bulló M, Ros E. The role of diet in the prevention of type 2 diabetes // Nutr Metab Cardiovasc Dis. 2011; 21 (Suppl 2): B32-48. https://doi.org/10.1016/j.numecd.2011.03.009
19. Korat A, Willett WC, Hu FB. Diet, lifestyle, and genetic risk factors for type 2 diabetes: a review from the Nurses' Health Study, Nurses' Health Study 2, and Health Professionals' Follow-up Study // Nutr Rep. 2014; 3 (4): 345-54. https://doi.org/10.1007 / s13668-014-0103-5
This work is licensed under a Creative Commons Attribution 4.0 International License.